85583-40-0

Basic information

• Product Name: Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-
• CAS NO: 85583-40-0
• Molecular Formula: C15H18N2O
• Molecular Weight: 242.321
• Mol File: 85583-40-0.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-(85583-40-0)
• EPA Substance Registry System: Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-(85583-40-0)

Safety Data

• Hazardous Substances Data: 85583-40-0(Hazardous Substances Data)

Usage

General Description

Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]-, also known as Vericiguat, is a chemical compound with potential therapeutic applications. It is a soluble guanylate cyclase stimulator that has shown promise in the treatment of certain cardiovascular diseases, particularly heart failure. By activating soluble guanylate cyclase, Vericiguat can increase cyclic guanosine monophosphate (cGMP) levels in the body, leading to vasodilation and improved cardiac function. Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]- has demonstrated the ability to reduce the risk of cardiovascular death and heart failure hospitalization in patients with chronic heart failure. Additionally, it has shown potential for the treatment of pulmonary hypertension and kidney disease. Overall, Benzenamine, 4-[2-(5-ethyl-2-pyridinyl)ethoxy]- represents a promising avenue for the development of novel cardiovascular therapies.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 5223-06-3 5-ethyl-2-(2-hydroxyethyl)pyridine 
• 85583-54-6 4-[2-(5-ethyl-2-pyridyl)ethoxy]nitrobenzene 

Downstream Products

• 105355-25-7 methyl 2-bromo-3-{4-[2-(5-ethyl-pyridin-2-yl)ethoxy]phenyl}propionate 
• 952188-01-1 1,3-bis-{4-[2-(5-ethyl-pyridin-2-yl)-ethoxy]-phenyl}-isothiourea 
• 881847-12-7 (+/-)ethyl-2-bromo-3-{4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}propionate 
• 1185263-65-3 methyl 2-chloro-3-{4-[2-(5-ethyl-2-pyridyl)ethoxyl]phenyl}propionate 
• 105355-27-9 Pioglitazone 
• 112529-15-4 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione hydrochloride 
• 101931-09-3 methyl 3-{4-[2-acetoxy-2-(5-ethyl-2-pyridyl) ethoxy]phenyl}-2-bromopropionate 
• 145350-19-2 methyl 2-bromo-3-{4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}propionate N-oxide 
• 101931-00-4 5-{4-[2-(5-ethyl-pyridin-2-yl)-2-hydroxyethoxy]benzyl}-2,4-thiazolidinedione 
• 105355-26-8 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2-imino-4-thiazolidinone 
• 669716-58-9 2-[2-(4-bromophenoxy)ethyl]-5-ethyl-pyridine 

Relevant articles and documents

Preparation method of piogelimide

The invention provides a preparation method of piogelimide, which comprises the following steps: by using 4-[2- (5-ethyl-2-pyridyl)ethyoxyl]nitrobenzene as a starting material, methanol as a solvent and Raney Ni as a catalyst, carrying out catalytic hydrogenation, carrying out pressure filtration on the reaction solution into hydrobromic acid to carry out acidification reaction, and adding cuprousoxide, methyl acrylate and acetone into the system; dropwise adding a sodium nitrite solution, drying the organic solvent by distillation under reduced pressure after the reaction is finished, addingammonia water, alkalifying the solution by using liquid caustic soda, and extracting the product by using ethyl acetate; and adding thiourea and sodium acetate into the ethyl acetate solution, performing heating reflux until the reaction is finished, cooling the reaction product, adding water, spin-drying the reaction product, and refining the product by using DMF to obtain a piogelimide finishedproduct. According to the method, the yield and purity of the product can be effectively improved, the raw material cost is greatly reduced, the production operation is simplified, the production efficiency is improved, and the influence on the environment is greatly reduced.

An improved process for pioglitazone and its pharmaceutically acceptable salt

An improved process for pioglitazone (1) is described. The process features high-yielding transformations employing inexpensive reagents and recoverable solvents.

Structural characterization of impurities in pioglitazone

In the pioglitazone bulk drug three prominent impurities I-III were detected up to concentrations of 0.1% (ranging from 0.05-0.1%) by reversed phase HPLC. These impurities were isolated from enriched mother liquor samples and characterized as 5-(4-hydroxybenzyl)-1,3-thiazolidine-2,4-dione (I) 5-(4-fluorobenzyl)-1,3-thiazolidine-2,4-dione (II), 2-[2-(4-bromophenoxy) ethyl-5-ethyl pyridine (III) based on their 1H, and 13C NMR, DEPT, Mass and IR spectral data. Structure elucidation and synthesis of these impurities is discussed.